Acute Drug Toxicity Data

Similar documents
Professor Paul I Dargan

Annual report 2012: the state of the drugs problem in Europe

Conventional and emerging drugs of abuse: the current situation

Norfolk & Suffolk Crime Prevention Guidance Note Legal Highs

Clinical Toxicology: An Update

The Challenge of New Psychoactive Substances (NPS) A Presentation for CAD by Dr Des Corrigan October 2015

HOSPITAL AND EMERGENCY SERVICES DATA CONTRACT CODE: CT.08.EPI

Risk Assessment of Psychoactive Substances: Potentialities and Limitations

NPS New Psychoactive Substances

Annual report 2009: the state of the drugs problem in Europe

Recent developments in the detection of harms arising from the use of synthetic cathinonesin Europe

Appendix 2: The nature and addictiveness of commonly used illicit drugs

Recent changes and new trends observed regarding drug use

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Substances under Surveillance

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

PERSPECTIVES ON DRUGS Emergency health consequences of cocaine use in Europe

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

NPS use, harms and health responses to NPS in Europe: findings form multi-method studies

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Crime and Justice. New Psychoactive Substances Evidence Review

factsheet New psychoactive substances: Who is this factsheet for? Why don t we call them legal highs? What are new psychoactive substances?

To the Maximus Foundation

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

The new psychoactive substances: Toxicity and management

Click for Support REALized

Novel Psychoactive Substances. Legal Highs. Dr James Dear

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Conflict of Interest Disclosure

A handful of dangerous new legal drugs has public health experts worried

World Drug Report 2017

Key findings for drug use patterns & drug markets

Lima - Peru, August 18-22, 2014

Statistics on Drug Misuse: England, 2012

WEDINOS Headlines 6,452. wedinos.org 5,806 BULLETIN. Samples. received. Samples. received. Samples. analysed. Samples. rejected

Drug related hospital stays in Australia

New Psychoactive Substances *NOT FOR HUMAN CONSUMPTION*

EMBARGOED NOT FOR RELEASE PRIOR TO AM WEDNESDAY OCTOBER

Improving our capacity of identification and reporting on emerging trends. New methods and new areas of analysis

about methodology of monitoring and selecting the web shops see methodology on trend.eu/).

2014 Key Australian findings: psychostimulant drug market

NPS use in Norway. Presented by Ellen J. Amundsen, Department of Alcohol, Tobacco and Drugs, Norwegian Institute of Public Health/ NIPH

Changing patterns of new and emerging psychoactive substances in Australia

In this article I am going to explore the use. Recreational drugs and their impact on diabetes. Article. Debbie Hicks

Academiejaar

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

The issues facing Europe

What is Drug Trends? funded by the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund

NIGHTLIFE QUESTIONNAIRE RECREATIONAL USEV7 core module / 2018

Results from the NPSinEurope.eu Project 5-Country RAR of New Psychoactive Drugs (NPS)

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

Drug trafficking via the darknet. Chloé Carpentier Chief, Drug Research Section 23 October 2018

Solving the ecstasy puzzle case study in the Netherlands

Global drug trends and sustainable development

National Drug Early Warning System (NDEWS) Los Angeles County Sentinel Community Site Appendix Data Tables, 2015

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

SA 15 REPORT ON THE ANALYZED SUBSTANCES IN SPAIN BY ENERGY CONTROL DURING 2015 A PROGRAM OF THE ASSOCIATION:

New patterns of drug use in Hungary

Minneapolis/St. Paul, Minnesota Drug Abuse Trends: January 2014 Update

Drug-related hospital stays in Australia

The EU Early Warning System: 20 years of monitoring New Psychoactive Substances in Europe

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

Statistics on Drug Misuse: England, 2007

39 th Expert Committee on Drug Dependence Process and recommendations

The European Early-warning system on new drugs. Dr. R. Sedefov & D. Lopez, Ancona, 18 September 2009

Substance briefing: MPPP

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

EWS in the Czech Republic country example

Developing a drug monitoring system for New Zealand: IDMS

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

Substance briefing: MDPPP

Amphetamine designer drugs an overview and epidemiology

Ecstasy and Related Drugs Reporting System: 2016 Findings

DRUGS AND THE INTERNET

INTER AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Czech web shop analysis found no web shop advertised branded products as containing 4-MEC substance.

Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot

Drug-related hospital stays in Australia

Czech web shop analysis did not find any web shop advertised branded products as containing MDPBP substance.

National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCE Narrative

EMCDDA trend report for the evaluation of the EU drugs strategy

Palm Beach County Substance Awareness Coalition. Drug Abuse Trends In Palm Beach County, Florida Annual Report: July 2017

Substance Abuse in US and Europe

An overview of the 2015 Ecstasy and Related Drugs. Reporting System. Ecstasy and Related Drugs. drug trends bulletin October 2015

Drugs and The Internet

National Drug Early Warning System (NDEWS) Texas Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center

Drug Trend Bulletin Issue 2 July 2015

EMCDDA Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA

WORLD DRUG REPORT 2011

Objectives. Why new drugs? New drugs of abuse: synthetic cannabinoids, stimulants, and 10/14/2015. Describe several new drugs of abuse

Analogue controls: An imperfect law

Forensic Toxicology Findings in DRDs. Dr Hazel Torrance Manager of the Forensic Toxicology Service Forensic Medicine and Science

Rob Ralphs Drugs and clubbing in an English city: An analysis of current trends and the implications for a harm reduction approach

Guide to common drugs

Jane Maxwell, UT Addiction Research Institute, Drug Trends: Old Drugs and New Problems - New Drugs and New Problems

Overview of drug-induced deaths in Europe - What does the data tell us?

The Art of being Human

Transcription:

Acute Drug Toxicity Data Recreational drug use is common Systematic data is available on: Prevalence of drug use Drug seizures Use of treatment agencies for problem drug use Drug-related fatalities There is no systematic data on acute recreational drug toxicity Despite this being a key public health indicator on

Currently Available National Data on Recreational Drug Toxicity Some sub-population hospital/pre-hospital data collected e.g. Spain, UK and Netherlands Recent EMCDDA study: cocaine Hospital coding of admissions (discharges) Only captures admitted patients (50%) Based on ICD-10: very poor coding capture - Many drugs not included - Many cases coded by the presenting feature

Data triangulation of information on new psychoactive substance toxicity Numerous sources of information on the acute toxicity of new psychoactive substances No single one provides the complete picture Each has its own limitations Traingulation combines the various sources to minimise the limitations and increase the strength of the combination Requires an understanding of the data sources

Data triangulation examples

Potential sources of information on novel drug use and toxicity In vitro pharmacological studies Animal studies User reports and sub-population surveys Poisons Information Services Pre-hospital emergency services data Clinical reports Case reports / series ED presentations, linked sentinel centres

In vitro pharmacological studies? Often very little known about their pharmacology or potential for toxicity Except some NPS which have been used previously in pharmaceutical industry More recent studies allow characterisation of likely pharmacological mechanisms of action Prediction of pharmacological activity and potential toxicity Need to interpret with caution

What about animal studies? Generally lag significantly behind other data sources

Internet based discussion forums Need to interpret with caution Self-reported by users, no corroboration BUT, can be useful source of initial information

Sub-population user surveys Examples: MixMag/GDS, in situ nightclub surveys, focus group surveys, internet surveys 454 (18%) medical help due to drugs 20% cathinones, 8% other NPS Data from most recent episode Collapse 32% Palpitations 30% Chest pain 29% Panic / paranoia 25% Hallucinations 22%

Poisons Information Services Provide information to clinicians on management of drug toxicity AND collect data on these cases Can collate data on Geographical and time patterns Clinical patters of toxicity

Poisons Information Service Data Potential useful source of data Can be useful in following trends in established NPS Need to interpret with caution May get multiple calls about one case Requires clinicians to contact poisons services AND to report all used drugs Needs awareness of the NPS by the poisons centre Early information often lags behind availability of NPS on the recreational drug market

Ambulance and pre-hospital data Ambulance data sets UK: >90% cases brought to hospital by ambulance Ambulance datasets not widely available/published - No standard EU / International coding system Data linkage occurs in some areas (e.g. Holland) Other pre-hospital facilities Data not routinely available but can be useful - e.g. ketamine pre- vs in-hospital

Case reports and case series Requires clinicians to be aware of NPS Initial reports tend to be based on user self-report Analytically confirmed cases are the gold standard Needs access and funding for specialist analytical facilities to confirm that cases are related to potential novel drug Analytical confirmation can be challenging and is costly

Specialist / Sentinel Centres Single centre datasets can collect detailed clinical data on prevalence of novel drug use May include links with specialist analytical facilities Requires interest (and finance) Particularly to monitor trends in areas with high volume drug use Single centres can be linked to allow comparison between different geographical regions

Number of presentations 300 250 200 150 100 50 Cocaine GHB/GBL MDMA Ketamine Cannabis Amphetamine Methamphetamine Volatile Nitrites LSD Magic Mushrooms Novel Pyschoactive Drugs 0 2006 2007 2008 2009 2010 Year of presentation

Euro-DEN Project European-Drug Emergencies Network Full scoping exercise on current European data collection Network of 16 specialist ED centres Clinical interest in drug toxicity Data collection over 1 year using minimum dataset Establish seasonal trends Compare drugs responsible for toxicity across Europe Document patterns of NPS toxicity Also night-time economy training in drug toxicity

Euro-DEN Project European-Drug Emergencies Network First 4 months of data from 13 (81%) centres 1290 cases Top 8 drugs: Heroin, cocaine, GHB/GBL, cannabis, amphetamine, MDMA, clonazepam, mephedrone NPS 126 (9.8%) cases in 6 (46%) countries UK, Poland, Germany, Spain, Norway, Switzerland

Classifying acute toxicity of new Established recreational drugs are clinically grouped together on the on basis of their unwanted effects Stimulants Hallucinogens Depressants psychoactive substances Management then guided by clinical pattern of toxicity rather than being drug/substance specific Is this also appropriate for NPS?

Novel Drugs Clinical Classification Stimulants Piperazines Cathinones Synthetic cocaine Pipradrols Indanes Benzofurans NBOMes Hallucinogens Glaucine Ketamine analogues Tryptamines Synthetic cannabinoids Salvia TFMPP Depressants GBL / 1,4-butanediol Novel opioids and metabolites

Some NPS have additional toxicity Methoxetamine Stimulant features Cerebellar toxicity Synthetic cannabionoid receptor agonists Stimulant features Pipradrols Prolonged neuropsychiatric features Increasing chemical & structural diversity of NPS Increases risk of additional, unexpected toxicity Potency is another concern (e.g. NBOMes) Wood DM Eur J Clin Pharmacol 2011 & 2012, Ward J Clin Tox 2012, Murray D Clin Tox 2012, Dargan PI Clin Tox 2012, Hofer KE Ann Emerg Med 2012, Hills S Clin Tox 2013

Conclusions Significant potential for acute harm associated with NPS No pan-european data collection systems on the acute harms related to novel substances Data triangulation from multiple sources allows patterns of acute toxicity to be determined Poisons information services can provide useful information: need to be co-ordinated Euro-DEN project is novel pan-european co-ordinated approach to collecting Emergency Department data The ideal would be an acute harm indicator for reporting to ECMDDA: hospital and poisons centre data